Status: Recruiting
A Clinical Study of GK02 in Malignant Ascites
A single-arm, single-center, open-label clinical study comprising three cohorts, evaluating the safety, preliminary efficacy, and pharmacokinetic/ pharmacodynamic (PK/PD) characteristics of autologous tumor-reactive T cells (GK02) derived from malignant ascites caused by advanced solid tumors. The trial initially plans to enroll 9 subjects with malignant ascites caused by advanced solid tumors.
Participants needed: 9
Trial details
Phase: Early Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Beijing Geekgene Technology Co., LTDUpdated: Jan 30, 2026Locations: 1
Eligibility criteria
Ability to understand and sign a written informed consent document； [+8]
Those with a history of severe allergies or allergic reactions to any components... [+10]